ClinicalTrials.gg
Not yet recruitingNCT06141980Updated Nov 21, 2023

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of DWP16001 0.3 mg in T2DM (Type 2 Diabetes Mellitus), sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Not applicable
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
9th of 15
134 · median 140
Started
2023
with 3 others
Phase 3
8 of 15
3 open now
Registered
11th of 15
by date
Lead sponsor
12 of 15
Daewoong Pharmaceutical Co. LTD.

Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 9th largest by planned enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About enavogliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period.

At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial.

The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.

Read the detailed description

The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. Throughout this period, subjects will receive concurrent administration of metformin (≥1,000 mg/day) and gemigliptin (50 mg/day), and will have a washout period for other oral antidiabetic drugs.

At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial.

The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with T2DM age 19 \~ under 80 years
  2. Subjects who have 7% ≤ ≤ 11% in screening visit(V1-1)
  3. Subjects who have FPG \<270 mg/dl screening visit(V1-1)
  4. Subjects who have received a combination of metformin (≥1,000 mg/day) and gemigliptin (50 mg/day) for a minimum of 8 weeks prior to Visit 2 (Enrollment Visit)
  5. Subjects who voluntarily decided to participate and provided written consent after being told of the objectives, method, and effects of this study

Exclusion criteria

Exclusion Criteria:

  1. Subjects with current or history of to the IP of this study, metformin or drugs of the same class and their components (e.g., history of hypersensitivity to biguanide or SGLT2 inhibitors)
  2. Diabetic ketoacidosis, diabetic coma or precoma within the past year
  3. Urinary tract infections or genital infections within
  4. Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg)
  5. \< 45 mL/min/1.73 m2
  6. Severe heart failure ( class III/IV
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Study group (DWP16001 0.3 mg)

    DWP16001 0.3mg, Tablets, Orally, Once daily

    Drug: DWP16001 0.3 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Safety outcomes_Adverse events occurred during clinical trials

    Safety outcomes_Adverse events occurred during clinical trials

    Time frame: from baseline up to 52 weeks

  2. Safety outcomes_ Change of blood pressure

    Safety outcomes_ Change of blood pressure

    Time frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP

  3. Safety outcomes_ Change of heartbeat

    Safety outcomes_ Change of heartbeat

    Time frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP

  4. Safety outcomes_ Change of body temperature

    Safety outcomes_ Change of body temperature

    Time frame: from baseline to Week 8, 16, 24, 38, and 52 after administration of the IP

  5. Efficacy outcome_Change of HbA1c

    Efficacy outcome_Change of HbA1c

    Time frame: from Baseline at Week 8, 16, 24, 38, and 52 after administration of the IP

  6. Efficacy outcome_Change of FPG

    Efficacy outcome_Change of FPG

    Time frame: from baseline at Week 8, 16, 24, 38, and 52 after administration of the IP

  7. Efficacy outcome_Proportion of subjects achieving HbA1c target of < 6.5%

    Efficacy outcome_Proportion of subjects achieving HbA1c target of \< 6.5%

    Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP

  8. Efficacy outcome_Proportion of subjects achieving HbA1c target of < 7.0 %

    Efficacy outcome_Proportion of subjects achieving HbA1c target of \< 6.5%

    Time frame: at Weeks 8, 16, 24, 38 and 52 after administration of the IP

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Sep 2025, 21 months later.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 21 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 21, 2023
StartEst.
Dec 2023
Primary completionEst.
Sep 2025
CompletionEst.
Sep 2025
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06141980
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Dec 2023 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Nov 21, 2023

Study contacts

Jayoung Shon
Contact
jyshon@daewoong.co.kr
+82-10-9811-6679
Soo Lim, MD, PH.D
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion